Back to Search
Start Over
Where Does Allogeneic Stem Cell Transplantation Fit in the Treatment of Chronic Lymphocytic Leukemia?
- Source :
- Current Hematologic Malignancy Reports; Mar2015, Vol. 10 Issue 1, p59-64, 6p
- Publication Year :
- 2015
-
Abstract
- Allogeneic hematopoietic stem cell transplantation (alloHSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (CLL) (i.e., refractory to purine analogs, short response (<24 months) to intensive treatments, and/or presence of 17p/ TP53 abnormalities). Currently, new and highly effective therapeutic agents targeting BCR-mediated intracellular signal transduction have been incorporated into the CLL treatment armamentarium. These signal transduction inhibitors (STI) will change the algorithms of high-risk CLL (HR-CLL) management. Despite the limited body of evidence, there is sufficient rationale for withholding alloHSCT in patients with 17p-/ TP53mut CLL in first remission. In contrast, the perspectives of patients with relapsed 17p-/ TP53mut CLL remain uncertain even if responding to STI. The same accounts for patients with HR-CLL progressing under STI. In both scenarios, it is reasonable to consider alloHSCT, ideally after response to alternative STI regimens. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 15588211
- Volume :
- 10
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Current Hematologic Malignancy Reports
- Publication Type :
- Academic Journal
- Accession number :
- 101421746
- Full Text :
- https://doi.org/10.1007/s11899-014-0242-1